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VARIABILITY OF BONE CELL GENE EXPRESSION AS A CRITERION TO 
DETERMINE OSTEOGENIC CAPABILITY OF HUMAN MESENCHYMAL 
STEM CELLS 
GABRIELA JULIET LOWRY 
ABSTRACT 
Osteoporosis is a skeletal disorder characterized by decreased BMD and the increased 
prospect of fracture. These fractures can have a detrimental impact on an individual’s 
standard of living and are sometimes fatal. Increased bone resorption by osteoclasts relative 
to the bone formation by osteoblasts triggers osteoporosis. Osteoporosis predominantly 
affects post-menopausal white and Asian women. BMD is used to diagnose this disease 
and determine fracture risks; however, osteoporosis often goes unreported and untreated. 
The purpose of this study was to correlate biochemical assays of bone growth with each 
subject's cells' gene expression grown in culture. Bone samples were taken from each 
subject undergoing hip replacement surgery. Each subject’s bone cells were grown in 
culture then assayed for ALP and hydroxyproline. ALP and hydroxyproline were used as 
proxies of the osteogenic potential of the cultured cells. The assayed ALP for each subject 
was compared to COL1A1 RNA gene expression. Further, the hydroxyproline assay results 
were compared to DMP1 RNA gene expression. The results of this study did not signal a 
measurable association between any of these metrics. The genetic mechanisms of 
osteoporosis remain unclear, and advanced research to elucidate how cells’ behavior in 
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culture is related to the underlying nature of the person’s BMD could result in better data 
to treat and prevent this disease.  
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Bone is a dynamic, biologically active, and adaptive connective tissue. The 
skeleton provides a framework to connect to ligaments and tendons for movement and 
enough rigidity to ensure structural support for the body and organ protection (Hart et al., 
2020). Bones provide the tissue niche for hematopoiesis and serve as a  reservoir for 
calcium and phosphate storage (Buck & Dumanian, 2012). 
Adults have approximately 200 bones, with various architectural shapes. The 
femur and humerus are generally long, load-bearing bones (Hart et al., 2020). They 
consist of three parts: diaphysis, metaphysis, and epiphysis, and generally make up the 
bones of the extremities. Many other bone shapes, such as short, flat, sesamoid, or 
irregular, have different structures to accommodate their function in the body (Buck & 
Dumanian, 2012). Bone has specific material properties that properly serve its functions, 
including resistance to bending, toughness (strength), and elasticity (Armas & Recker, 
2012). The shape and makeup of bone are critical to its load-bearing ability and strength 
(Hart et al., 2020). Besides three-dimensional structure, different bones in the body also 
differ in density and metabolic activity (Buck & Dumanian, 2012). 
At a macroscopic level, there are two types of bone: cortical and cancellous. 
Cortical bone, known as compact bone, is thick and dense with low porosity and makes 
up approximately 80% of skeletal mass. Cortical bone surrounds all bones, providing 
compressive strength. Cancellous bone, known as trabecular bone, is a meshwork of bone 
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with high porosity that provides spaces in the bone to allow for other cells to reside in the 
bone marrow. This type of bone is generally metabolically active. The proportions of 
these two bone types vary depending on the needs of that bone in its specific location 
(Buck & Dumanian, 2012; Hart et al., 2020). 
There are two histological types of bone, woven and lamellar. Woven bone, 
known as immature bone, is found only in embryonic bone growth or early in fracture 
healing. Woven bone consists of random unorganized collagen and mineral matrix and is 
highly cellular. As people age, lamellar bone replaces the woven bone. Lamellar bone, 
known as mature bone, is highly organized, made of concentric sheets that increase 
strength and withstand load (Hart et al., 2020). The primary structural unit is the osteon 
shown in Figure 1. Osteon formation improves the structural integrity of bone in the long 
axis. Outside of the endosteum of the bone lies the periosteum. It serves as a connection 





Figure 1. Diagram of components of bone (Buck & Dumanian, 2012). 
 
Osteoclasts, osteoblasts, osteocytes, and bone lining cells are the main types of 
cells that make up bone. Osteoblasts, osteocytes, and bone lining cells originate from 
mesenchymal cells, while osteoclasts originate from hematopoietic cells (Buck & 
Dumanian, 2012; Hart et al., 2020). 
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Mesenchymal cells (MSCs) can differentiate into various mesenchymal tissues, 
such as fat and bone. MSCs are stem cells and differentiate into osteoprogenitor cells that 
are committed to the bone forming lineage. The two-step differentiation process for 
MSCs includes lineage commitment, MSC to osteoprogenitor; and maturation, 
osteoprogenitor to osteoblast. Bone induction factors are required to signal the MSCs. 
Multiple factors can signal differentiation, such as chemical, physical, or biological 
signals. These bone induction factors then trigger a signaling pathway that leads to the 
differentiation of MSCs to osteoblasts. This process is shown in Figure 2 below. 
Dysregulation or malfunction of this system can develop multiple pathologies such as 
osteopenia or osteoporosis (Q. Chen et al., 2016; Karaguzel & Holick, 2010). 
 
 
Figure 2. Key signal pathways and transcription factors in MSC adipo-osteogenic differentiation (Q. 
Chen et al., 2016). 
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The bone liver kidney isoform of Alkaline phosphatase (ALP) is an early marker 
that signals bone growth. Osteoprogenitor cells differentiate to osteoblasts and migrate to 
the site where they are needed. Osteoblasts create and calcify new collagen and have 
three possible fates. The first is to become quiescent. If the cells are not needed, they stay 
as osteoblasts and return to the available cell pool until another signal is received. The 
second possibility is to become osteocytes. Once the osteoblasts build up a bone matrix in 
the space left by the osteoclasts, they become encased in a mineral matrix and are housed 
in lacunae. These encased osteoblasts are known as osteocytes. Osteocytes constitute 90-
95% of all bone cells. Though embedded separately in bone, they connect through 
dendritic processes called canaliculi, allowing signaling to promote bone growth or 
remodeling in damage or fracture cases (Hart et al., 2020). Osteocytes are the major 
signaling cell with bone tissues. The third possibility for activated osteoblasts is returning 
to osteoprogenitor cells to be differentiated when needed (Buck & Dumanian, 2012). 
Osteoclasts are resorptive bone cells that are hematopoietically derived. The 
hematopoietic precursor cells further differentiate into monocyte/macrophage 
progenitors. The fusion of these progenitors creates osteoclasts, and as such, mature 
osteoclasts are multinucleated. Their differentiation is regulated by RANK (a 
macrophage stimulating factor) and osteoprotegerin. Figure 3 shows the signaling 





Figure 3. Mechanism of osteoclast formation and osteoclast bone resorption (Teitelbaum, 2000) . 
 
 
Osteoclasts first attach to bone by forming an infolding of the cell’s plasma 
membrane, known as a "ruffled membrane," which only occurs when in contact with 
bone. At the ruffled membrane, surface acid is secreted onto the bone through vesicle 
transport and the bone becomes demineralized. The osteoclast then endocytoses the bone 
product and transports it elsewhere (Teitelbaum, 2000). 
Bones are continually remodeled through a tightly linked degradation by 
osteoclast and reforming through osteoblasts. (X. Chen et al., 2018). Bone is a dynamic 
tissue: osteoclasts resorb, and osteoblasts lay down bone in a tightly regulated process 
that leads to a wholly renewed skeleton every seven years (Q. Chen et al., 2016). 
Communication between osteoclasts and osteoblasts is critical for the homeostatic 
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interactions between these two cells. The cells communicate through various methods, 
including direct cell contact, cytokines, and interaction with the extracellular bone matrix 
(Chen et al., 2018). When the balance between bone resorption and bone formation 
becomes skewed, diseases such as osteoporosis can arise (Teitelbaum, 2000). 
The coupled response between osteoblasts and osteoclasts is normally regulated to 
ensure maximum bone strength. Older osteoblasts lay down the bone matrix and 
transform into osteocytes, which make up 95% of bone, increasing the bone's strength 
and mass (Hart et al., 2020). The critical component to bone strength is the bone matrix. 
Osteoblasts mineralize calcium and phosphate components to make calcium phosphate, 
known as hydroxyapatite, giving bone its structure. Osteoclasts function to resorb this 
material, turning hydroxyapatite back into soluble calcium and phosphate. This inorganic 
component of the bone matrix accounts for 99% of the body's calcium store and a 
majority makeup of the bone. The rest of the bone matrix consists of organic material, 
lipids, and water (Buck & Dumanian, 2012). The most common extracellular organic 
material in bone is collagen, necessary for bone flexibility. The bone matrix provides 
resistance against compression and torsion and provides a support framework for the 
body. The bone must be strong enough to withstand forces and flexible enough to 
accommodate some deformation; it must withstand a certain amount of torsion, 
compression, and pulling (Hart et al., 2020). 
In a developing fetus, bone growth occurs through either endochondral 
ossification or intramembranous ossification. Endochondral ossification occurs with long 
bone formation or bones with a growth plate. It requires an intermediate cartilage step 
 
8 
before the formation of bone. As the fetus develops, chondrocytes proliferate where the 
bone will grow, then they hypertrophy. As they hypertrophy, the chondrocytes release 
ALP to signal the next step in development. The chondrocytes then undergo apoptosis, 
leaving space for osteoblasts to form a new bone matrix. Intramembranous ossification 
happens with flat bone formation; it has no cartilage intermediate, and it occurs primarily 
in bone healing and distraction osteogenesis. Various hormones signal bone modeling. 
This growth occurs primarily in the first 30 years of life, and multiple genetic factors 
influence bone development and BMD, while multiple environmental factors including 
nutrition, physical activities and hormones can affect BMD. For positive bone growth to 
occur, osteoblasts and osteoclasts work together; however, osteoblast bone formation 
must exceed osteoclast bone resorption (Buck & Dumanian, 2012). 
Bone remodeling is a continuous, highly regulated process in which old bone is 
dissolved by osteoclasts and replaced by new bone-formed osteoblasts. Remodeling 
occurs in three steps: (1) resorption, (2) reversal, and (3) formation. Osteoclasts are 
responsible for resorption, wherein they dissolve bone matrix and signal osteocyte 
apoptosis to create space for new bone formation. Reversal is the process where 
osteoblasts form new bone matrix, while osteoclast activity ceases as they undergo cell 
death. Finally, formation is how osteoblasts lay down new bone material and become 
embedded in the bony matrix (Hadjidakis & Androulakis, 2006). 
Remodeling arises in response to two stimuli: damage and nutrient need. In the 
first instance, mechanical damage to the bone, which can be microscopic or a more 
significant fracture, is detected and signaled by the osteocytes. Osteoclasts are recruited 
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to the site of damage to remove the weakened bone. This state is transiently weak; 
however, this process is necessary to maintain the strength of bone. Osteoblasts closely 
follow osteoclasts and rebuild new bone in the space left by bone resorption. This new 
bone matrix strengthens the existing bone and maintains homeostasis. Different loads, 
torsion, and angles of force can affect the bone differently, leading to strengthening or 
damage (Hart et al., 2020).  
In malnutrition, osteoclasts are signaled to resorb bone material so that calcium 
and phosphate are sent into the bloodstream to be used elsewhere in the body. If one stays 
in a constant state of malnutrition, this perpetual remodeling to compensate for lack of 
calcium can damage the structural integrity of the bone (Armas & Recker, 2012).  
Multiple conditions can cause overall bone degradation, the most common result 
from age. Over time, bone mass loss can occur due to dysregulation of integrated 
osteoclast-osteoblast activity, driving osteopenia and osteoporosis conditions. Bone 
degrades from disuse due to immobility, paralysis, or long-term zero gravity experienced 
by astronauts. On the other hand, excessive mechanical loads or overuse without taking 










Osteoporosis is a skeletal disorder characterized by decreased bone density and 
mass, which compromises the bone's structural integrity, predisposing individuals to 
fractures. The most common fractures are in the vertebrae, hip, and wrist (Osteoporosis 
Overview | NIH Osteoporosis and Related Bone Diseases National Resource Center, 
n.d.). Two hundred million people are estimated to have osteoporosis, and one in three 
women over the age of 50 will experience an osteoporosis-related fracture in their 
lifetime (Sözen et al., 2017). More than 8.9 million osteoporosis-related fractures happen 
worldwide every year (Epidemiology of Osteoporosis and Fragility Fractures | 
International Osteoporosis Foundation, n.d.). In the U.S., fractures related to 
osteoporosis cost the national healthcare system an estimated $17 billion per year, with 
costs steadily rising (Lane, 2006). There is also a personal burden associated with 
osteoporosis, including disruption of one's life and activities along with potential loss of 
employment (Barker et al., 2016). As the elderly population grows, the incidence of 
osteoporosis and its related fractures will continue to become more prevalent. 
Osteoporosis, characterized by low BMD and decreased bone strength, leads to 
structural instability and often fracture. A view of osteoporotic bone compared to normal 
healthy bone is shown in Figure 4. Individuals with osteoporosis have decreased 
trabeculae, both in volume and number, lowered remodeling, cortical bone loss along the 




Figure 4. Slides of normal bone and osteoporotic bone (Aspray & Hill, 2019). 
 
Three main components of bone health can lead to osteoporosis and fracture: 
defects in the trabecular microarchitecture of the bone, material properties of the bone, 
and defective remodeling after damage. In normal physiological function, microdamage 
causes microfracture in the bone. These fractures disrupt the communication between 
osteocytes, triggering osteocyte apoptosis, which causes a bio-signaling cascade that 
triggers the differentiation of osteoclasts and osteoblasts and their migration to the site of 
damage. Osteoclasts then secrete hydrochloric acid and cathepsin K to dissolve the bone 
matrix. Osteoblasts lay down a mineralized collagen matrix. Osteoblasts then become a 
part of the mineralized matrix and are then known as osteocytes that interact with each 
other and play a role in cell signaling. Bone balance is the relative amount of resorption 
and deposition. A bone balance that diverges from the standard indicates a pathology 
(Armas & Recker, 2012). 
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Osteoporosis arises from a negative bone balance, wherein osteoclast bone 
resorption exceeds osteoblast bone formation (Teitelbaum, 2000). In early life, bone 
growth exceeds resorption, continuing into early adulthood until one reaches maximum 
bone density at ages 30-40 (Aspray & Hill, 2019). Bone remodeling or growth response 
occurs in the bone marrow, as MSCs convert to osteoblasts (Bidwell et al., 2013). As a 
person ages, one gradually loses bone mass (Aspray & Hill, 2019). The precursor cells' 
phenotype leads to bone growth change with age and decreased estrogen (Bidwell et al., 
2013).  
The three broad types of osteoporosis are senile osteoporosis, sex steroid 
deficiency osteoporosis, and secondary osteoporosis (Bidwell et al., 2013). Senile 
osteoporosis arises in frail older adults when their cellular mechanisms fail to function 
efficiently. Sex steroid deficiency osteoporosis ensues in post-menopausal women with 
lowered estrogen. Secondary osteoporosis emerges from other diseases or treatments, and 
the side effect is osteoporosis (Armas & Recker, 2012). 
The typical individual with osteoporosis is post-menopausal, slight, with 
decreased weight-bearing activity and low calcium intake (Bidwell et al., 2013). One of 
the significant causes of osteoporosis for this at-risk group is an estrogen deficiency. Loss 
of estrogen seen in menopause has the secondary effect of decreasing osteoclasts' 
inhibition, which increases both the activity and lifespan of the osteoclasts. The body 
compensates by increasing the formation of osteoblast cells; however, this effect does not 
account for the increased osteoclast activity (Armas & Recker, 2012). Various studies 
have shown that post-menopausal women experience an increase in bone loss and bone 
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formation; however, the process of bone maintenance becomes uncoupled, resulting in 
increased resorption relative to deposition, leading to bone loss (Aspray & Hill, 2019). 
 
 
Diagnosis of Osteoporosis 
The current standard of diagnosing osteoporosis uses clinical test metrics and risk 
factors that combined indicate the likelihood of an osteoporotic fracture. One of the 
critical metrics for assessing osteoporosis is BMD. BMD testing estimates mineral 
content in the bone representing bone strength (Aspray & Hill, 2019). BMD peaks around 
age 30 and gradually declines after that. The likelihood of being diagnosed with 
osteoporosis depends on this peak bone mass achieved in young adulthood (Armas & 
Recker, 2012). Twin studies have shown that BMD is strongly correlated with identical 
twins, indicating that it is highly genetically regulated (Pocock et al., 1987); though, 
some noted variability is due to environmental factors (Smith et al., 1973). 
Dual-energy X-ray absorptiometry (DXA) measures BMD. An X-ray passes 
through certain bones, and the attenuation of the beam quantifies the mineral density of 
the bone. The DXA returns a T-score that references how much higher or lower a 
measured BMD is compared to that of a healthy 30-year-old. T-scores are assigned in 
standard deviations below normal. Any standard deviation above -1 is considered 
“normal” or healthy bone. The World Health Organization (WHO) approximates that 
every decrease in the standard deviation of 1 doubles the risk of an osteoporotic fracture 
(Curtis et al., 2017). A T-score between -1 and -2.5 indicates a lower-than-average bone 
 
14 
density, a condition known as osteopenia. Any T-score below -2.5 indicates a possible 
osteoporosis diagnosis (Bone Density Test, Osteoporosis Screening & T-Score 
Interpretation, n.d.). 
While BMD can approximate the likelihood a person has of experiencing a 
fracture, there are some caveats. For example, a child and an older adult may have the 
same BMD, but the child has a much lower likelihood of experiencing a fracture as they 
are still developing to their maximum bone density. Additionally, the use of BMD is 
limited in that it cannot detect differences in geometry or distinguish between cancellous 
or cortical bone (Rachner et al., 2011).  
In the past, BMD was used to define and diagnose osteoporosis. DXA calculated 
T-scores help determine osteoporosis treatment thresholds; however, relying exclusively 
on this metric excludes many individuals at risk for fracture outside these clinical bounds. 
Other components, such as an individual's risk factors and architectural properties of the 
bone, also impact fracture risks. Currently, the most frequently used assessment tool for 
osteoporosis management is the Fracture Risk Assessment Tool (FRAX). The indicators 
used in the FRAX tool include age, sex, BMI, the incidence of previous fractures, family 
history of fractures, smoking status, glucocorticoid use, and rheumatoid arthritis status 
(Rachner et al., 2011; FRAX Tool). This online tool combines clinical risk factors with 
measured BMD to calculate the overall 10-year risk of osteoporosis fracture. This data 
guides an individual's treatment and management (Curtis et al., 2017) 
Currently, osteoporosis is diagnosed with a measured BMD and FRAX analysis, 
or if a fracture occurs without significant trauma. Osteoporosis often goes undetected 
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unless a fracture occurs. Bernatz et al. conducted a study to assess the number of patients 
undergoing total joint arthroplasty who had undiagnosed or untreated osteoporosis. They 
found that around a quarter of the patients met the criteria to receive osteoporosis 
pharmacotherapy; however, only 5% had received these medications. The study 
concluded that the lack of treatment could lead to increased post-surgical periprosthetic 
fracture risk. This data, however, speaks to a more significant issue, that many 
individuals with osteoporosis go unrecognized and therefore untreated (Bernatz et al., 
2019). 
Combined with risk factors, a critical component of most osteoporosis diagnoses 
is a fall. A fall, defined as "an event which results in a person coming to rest 
inadvertently on the ground floor or other lower-level,” can cause serious injury, 
especially fractures (Falls, n.d.). In the study of osteoporosis, falls are usually only 
considered from a standing height, as falls from any higher can cause a fracture in most 
individuals regardless of age or osteoporotic status. A range of factors can influence the 











Chronic Diseases Acute Conditions Quality of surrounding 
environment (impediments, 
lighting) 
Impaired cognition Delirium Distractions (pets, 
children) 
Alcohol or substance 
abuse 
Side effects of medications Socioeconomic factors 
(poverty, living 
accommodations) 
Arthritis Dizziness Occupational hazards 
Sarcopenia/ loss of muscle 
mass or function  
Syncope Lack of accommodations 
(hearing aids, walkers, 
footwear) Malnutrition  
Visual impairment 
Age-related conditions 
(issues with gait, balance, 
mobility)  











Risk Factors for Osteoporosis 
 
Generally, fracture risk is not assessed before the age of 50 unless an individual 
has significant risk factors, such as a previous fragility fracture, early menopause in 
women or hypogonadism in men, or exogenous glucocorticoids. To assess fracture risks 
after the age of 65 in women and 75 in men, certain risk factors, including a family 
history of fracture, a personal history of falls, low BMI, smoking, alcohol use, and 
secondary osteoporosis, are considered (Aspray & Hill, 2019). Currently, the National 
Osteoporosis Foundation (NOF) recommends women over 65 and men over 70 receive 
BMD screening. Women under 65 who have already undergone menopause or any 
individual with additional risk factors, including broken bones after age 50 or height loss, 
should undergo BMD screening (Epidemiology of Osteoporosis and Fragility Fractures | 
International Osteoporosis Foundation, n.d.; (Curtis et al., 2017). 
Various clinical factors impact the chances of developing osteoporosis, including 
BMD, bone turnover, muscle mass and development, and bone architecture. Early and 
fetal development can impact an individual's bone health, including the mother's health 
and lifestyle, especially vitamin D and calcium intake (Aspray & Hill, 2019). Additional 
factors include age, sex, race, environmental factors, genetics, and secondary 
osteoporosis causes. 
Due to a post-menopausal decrease in estrogen, older women are 
disproportionately more at risk of developing osteoporosis than men. On average, 
osteoporosis affects 30% of women and 12% of men in their lifetimes. The lifetime risk 
of developing osteoporosis in white women over 50 is about 50% (Armas & Recker, 
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2012). As women undergo menopause, BMD declines markedly. Menopause is the 
cessation of menstruation, accompanied by decreased estrogen and progesterone 
production. It occurs in women between the ages of 40 and 60, with the average woman 
experiencing menopause at 51 years of age (Menopause - Symptoms and Causes, n.d.). 
Estrogen functions to inhibit osteoclast resorption of bone. When endogenous estrogen 
declines due to menopause, this inhibition also declines. Studies show that in the 5-7 
years that women typically undergo menopause and experience postmenopause, they lose 
about 12% of their bone mass, especially in trabecular bone (Recker et al., 2000). 
Fracture risk increases from age 40 well into 90 years of age. Generally, at around age 
70, men's risk of an osteoporotic fracture increases to equal women (Aspray & Hill, 
2019). Of note, while women are more likely to have osteoporosis or experience an 
osteoporotic fracture, studies have shown that men are more likely to die from such a 
fracture (Pietschmann et al., 2009). 
The risk of fracture varies depending on sex and age. In childhood and early 
adulthood, males are disproportionately more likely to experience a fracture than females. 
This risk in young males is likely due to the way boys are socialized and not due to a 
difference in physiology, as young men statistically have a slightly higher BMD than 
young women. However, past the age of 50, women are much more likely than men to 
experience a bone fracture (Aspray & Hill, 2019). Animal-based studies have shown that 
older bones can still sense force and load-based stimuli; however, the cells' ability to 
respond to these stimuli decreases (Galea et al., 2017). 
 
19 
Certain family studies have shown that while environment plays a role in 
osteoporosis development, genetics has been the major contributor to developing 
osteoporosis (Guéguen et al., 1995). There is a vital genetic component in an individual's 
BMD relative to the population, although external factors, including an individual's diet 
and lifestyle, can mitigate this genetic influence (Ralston & Crombrugghe, 2006). 
Race and ethnicity play a role in variances in osteoporosis risk in a population, 
specifically in BMD. A study conducted by Barret-Connor et al. found that BMD 
measured at specific bone sites predicts fractures reasonably well. Ethnic differences in 
weight have a significant impact on BMD for each group. Black women have the highest 
average BMD, and Asian women have the lowest. This study found that white and 
Hispanic women were most likely to experience fractures after normalizing BMD and 
weight. The BMD of each group influenced their respective risk of fracture (Barrett‐
Connor et al., 2005).  
Geography may contribute to some of these racial variances in osteoporosis risks. 
Hip fracture incidence has increased over the last half of the 20th century. In Asia, 
osteoporotic fractures have been increasing, while the incidence in North America and 
western Europe has been plateauing (Curtis et al., 2017). Osteoporotic fracture risk has 
been steadily increasing in developing countries, affecting millions worldwide. 
Generally, the most recorded osteoporotic fractures occurred in Europe, Russia, and 
North America, while lower-risk areas include Latin America and Africa. The trend 
generally follows that areas further from the equator, more specifically a constant source 
of vitamin D, are more likely to be at higher risk for osteoporosis; therefore, ethnicity 
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may contribute to measurable discrepancies in bone density differences (Curtis et al., 
2017). A family history of osteoporotic fracture is also a good indicator of individual 
risk.   
Calcium and vitamin D play an essential role in various diseases in bone, 
including but not limited to osteoporosis, nutritional osteomalacia, and rickets. In 
osteoporosis, the recorded deficiency in calcium or vitamin D occurred many years 
before osteoporosis's clinical manifestation. Exogenous calcium or vitamin D 
supplements have not been shown to reverse the effects of osteoporosis once present. 
Various studies indicate that an individual's vitamin D intake does not correlate with 
fracture risk over a short-term trial compared to long-term calcium supplementation 
studies that indicated a correlation between lowered fracture risk and increased calcium 
intake (Aspray & Hill, 2019). Studies have indicated that increased blood 25-(O.H.) 
vitamin D is correlated to BMD between ages 30 and 50; however, this conclusion did 
not extend to black or Hispanic individuals (Bischoff‐Ferrari et al., 2009). 
Further studies have shown that exogenous vitamin D supplementation positively 
impacted women's BMD if they started with a vitamin D deficiency (Macdonald et al., 
2018), while others noted, these data do not indicate any benefit to prevent fracture 
associated with calcium or vitamin D supplementation (Aspray & Hill, 2019). Research 
further shows that specific behavioral patterns can increase osteoporosis progression; for 
example, smoking decreases BMD and lowers bone turnover (Jorde et al., 2019).  
The most significant contributor to osteoporotic fracture, especially in aged 
populations, is a fall. Approximately 20-33% of older people fall every year. Multiple 
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interventions decrease falls in the elderly, including assessing home safety, assessing 
vision, physical therapy, and nutritional therapy. 10-15% of falls result in significant 
injury (Peel, 2011).  
Other factors, common in the elderly, increase the rate of falls and fractures, 
including lack of mobility, cancer treatments, dementia, diabetes mellitus, and obesity. 
Another oft-forgotten cause contributing to the rate of falls is polypharmacy, or the use of 
many drugs to treat various conditions, which can interact in unforeseen ways, causing 
adverse reactions, including decreased balance and impaired decision-making. Several 
other dynamics can also impact an individual's increased fracture risk or likelihood to 
develop osteoporosis, including socioeconomic status, life expectancy, and education 
(Aspray & Hill, 2019).  
Another element affecting bone health is adiposity. As osteoblasts and adipose 
cells derive from the exact MSC origin, there is a significant critical interaction between 
adipose tissue and bone. Three main mechanisms characterize this interaction: (1) the 
secretion of cytokines by the adipose tissue influences bone, (2) the secretion of 
adipokines by adipose tissue that impacts the CNS and its relation to bone, and (3) the 
secretion of paracrine hormones interacts with bone adjacent to the fat tissue. In a healthy 
adult, bone marrow content becomes increasingly infiltrated with adipose cells. The 
increase in adiposity and associated decrease in bone cells leads to bone loss and BMD, a 
normal aging part. Through the mechanisms shown above, increased adipose tissue, as 
seen with obesity endemic to the Western world, could impact the bones' incidence of 
pathophysiologies, particularly osteoporosis (Kawai et al., 2012).  
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Secondary osteoporosis stems from other medical conditions, which lead to a 
decrease in bone strength and possible fracture. Table 2 below examples of some such 
diseases. There are also specific medical therapies associated with reduced bone mass, 
including glucocorticoids, anticonvulsants, and benzodiazepines, to name a few (Aspray 
& Hill, 2019). 
 
 
Menopause  Cushing’s disease 
Hyperthyroidism Diabetes mellitus  
Hyperparathyroidism Celiac disease 
Hyperprolactinemia IBS 
Homocystinuria Multiple myeloma 
Chronic kidney disease Rheumatoid arthritis 
COPD Cystic fibrosis  
Osteomalacia  Hemoglobinopathies 
Corticosteriod treatment  Immobility/disuse 
Table 2: Conditions and risk factors that lead to secondary osteoporosis (Armas & Recker, 2012; 







Treatment of Osteoporosis 
The goal of osteoporosis therapy is to return the bone to its previous BMD and 
maintain bone strength while also preventing osteoporotic fracture. The U.S. Surgeon 
General has reported a few current osteoporosis therapies as potentially effective, 
including Ca and vitamin D supplements, physical activity, fall prevention, treating 
secondary causes, pharmacotherapy (Gass & Dawson-Hughes, 2006). 
The efficacy of calcium and vitamin D supplementation to improve the effects of 
osteoporosis is controversial; however, studies indicate that calcium and vitamin D intake 
in early life can increase an individual's peak bone mass density, thereby improving 
chances of maintaining adequate BMD to reduce fracture risk (Black & Rosen, 2016).  
Many pharmacotherapy treatments are available for osteoporosis, defined by two 
general categories: antiresorptive, which targets osteoclasts, and anabolics that target 
osteoblasts (Black & Rosen, 2016). Clinical studies have shown that antiresorptive drugs 
effectively manage fracture risk with osteoporosis for two main reasons. The first is that 
these drugs serve to increase BMD. The second, and perhaps more relevant, is that 
antiresorptive drugs decrease the rate at which bone is remodeled (Cummings et al., 
2002). 
The most prescribed antiresorptive drugs are bisphosphonates, estrogen-based 
treatments, and denosumab. Bisphosphonates treat osteoporosis by repressing remodeling 
by inhibiting osteoclasts and reducing the excessive resorption of bone characteristics 
with osteoporosis. Denosumab is a monoclonal antibody approved by the FDA to treat 
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osteoporosis. It reduces fracture risks by inhibiting bone resorption by binding to one of 
the osteoclast receptor activators (Black & Rosen, 2016; Tella & Gallagher, 2014). 
Both treatments may cause undesirable long-term effects, such as weakened bone 
strength, and are not effective in patients with already low BMD (Beard, 2012). 
Bisphosphonates reduce fracture risk, but they can also occasionally cause hypocalcemia 
or muscle pain. Rarely, bisphosphonates can cause atypical femoral fractures or 
osteonecrosis of the jaw. Common side effects of denosumab are UTIs, respiratory 
infections, cataracts, and joint pain (Tella & Gallagher, 2014). 
Another known antiresorptive treatment is estrogen and selective estrogen 
receptor modulators. As mentioned above, estrogen affects all bone cells but has a 
particular influence on osteoclasts' function. WHI trials have shown estrogen therapy 
reduces fracture incidence, but it is not recommended as a primary therapy against 
osteoporosis due to estrogen therapy concerns, including increased incidence of breast 
cancer, coronary, cerebrovascular, thrombotic issues. Selective estrogen receptor 
modulators inhibit bone resorption and have shown efficacy in decreasing spinal 
fractures. Like exogenous estrogen treatments, these drugs are not recommended as a 
first-line defense because they increase the chances of thromboembolic issues (Black & 
Rosen, 2016). 
Currently, teriparatide is the only FDA-approved anabolic osteoporosis treatment 
known to increase bone growth (Kraenzlin & Meier, 2011). Patients with low BMD who 
are not candidates for bisphosphonate treatment often receive teriparatide, a human 
parathyroid hormone (PTH), to reduce fracture risk (Black & Rosen, 2016). PTH 
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increases the number of osteoblasts differentiated from precursors and extends the 
lifetime of already formed osteoblasts by reducing apoptosis. This treatment is not 
approved for long-term use and is only a reasonable treatment in the short term (Aslan et 
al., 2012; Bidwell et al., 2013; Jilka, 2007). 
Most pharmacotherapy treatments presently available for osteoporosis are 
effective but have adverse side effects that preclude their use for longer than a year (Gass 
& Dawson-Hughes, 2006). Many clinical trials are currently underway with multiple 
potential new avenues to further treat osteoporosis in the growing elderly population 
(Rachner et al., 2011). Recent experimentation with adult MSCs can be used in 
conjunction with an osteo-compatible scaffolding matrix to increase the rate of bone 
healing at sites of bone fracture (Iaquinta et al., 2019). Mesenchymal progenitor 
transplant is a possible treatment for bone, cartilage, and muscle disorders. Bone marrow 
transplant was tested in children with osteogenesis imperfecta, a disorder in which 
osteoblasts do not produce functioning type I collagen. This experiment revealed 
increased BMD associated with increased height and decreased bone fractures (Horwitz 
et al., 1999). Platelets are essential to bone remodeling. Literature review studies have 
found a correlation between platelet size and bone regeneration. This discovery provides 
a potential new avenue for osteoporosis treatment, either as a metric to detect 
osteoporosis or a therapeutic avenue to target platelets for increased osteogenic capability 
(Salamanna et al., 2020).  
Despite these, the primary treatment most often considered for osteoporosis is 
prevention. To prevent osteoporosis, one must maximize BMD. BMD generally peaks in 
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early adulthood, with a considerable variation of BMD and bone mineral content across 
the population. For women, early bone growth is pronounced during and immediately 
post menarche. BMD increases, and bone mineral content (BMC) decreases around two 
years after menarche. Skeletal mass accumulated in women during adolescence is a 
considerable determinant of future osteoporosis after menopause (Theintz et al., 1992).  
To lower the risk of fracture, individuals over the age of 65 receive a BMD 
measurement along with a FRAX assessment (Black & Rosen, 2016). Additionally, 
women are encouraged to stay active, maintain a healthy lifestyle, and focus on resistance 
and weight-bearing exercises that benefit skeletal microarchitecture (Baccaro et al., 
2015). Modification of risk factors has also been recommended, including home 
assessment for fracture risk and smoking cessation.  
Osteoporosis prevention and treatment have been difficult to realize due to a 
general lack of information on the topic. Individuals often have inadequate knowledge of 
risk factors, treatment, and prevention of osteoporosis. Osteoporosis treatments are often 
not reported for men, and some are only studied and used in women (Pietschmann et al., 
2009). Education in these areas may benefit the future maintenance of osteoporosis 









For this paper, specific biochemical markers of osteogenic growth were used to quantify 
the bone cell metabolic activity. As bone forms, osteoblasts produce primarily type I 
collagen and some non-collagenous proteins, including ALP. Bone-specific ALP is a 
marker of bone formation (Unnanuntana et al., 2010). Hydroxyproline is used to make up 
collagen. This amino acid makes up 13% of the amino acids in collagen and is critical to 
its formation. After collagen is broken down, hydroxyproline is released and cannot be 
reused. Excreted collagen can be used as a metric to measure bone breakdown and 
turnover (Zaitseva et al., 2015; Zorab et al., 1971). 
 
Genes of Interest  
This study focused on two genes to determine osteoblastic differentiation: 
COL1A1 and dentin matrix protein 1 (DMP1). 18S RNA was used as a normalization 
constant for qRT-PCR, constitutively expressed (Kuchipudi et al., 2012). COL1A1 is a 
gene that encodes type I collagen. Studies have shown that specific polymorphisms in the 
COL1A1 gene result in BMD differences (Grant et al., 1996). This gene is the first in the 
pathway of genes that lead to osteogenesis, and it is expressed by most osteoblasts, 
indicating initiation of bone growth. For this study, it will be used as a metric to measure 
osteoblastic differentiation. DMP1 is a non-collagenous, acidic phosphoprotein required 
for late-stage bone mineralization. It appears late in the bone formation process, secreted 
after osteoblasts are committed to becoming osteocytes (Toyosawa et al., 2001). DMP1 
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acts as a transcription factor to mineralize bone, indicating bone cells have reached their 




Studies have shown that an increase in osteoclast activity compared to osteoblasts 
causes the clinical manifestations in osteoporosis patients. This study aims to correlate 
biochemical assays of bone growth with each subject's cells' gene expression grown in 
culture and hypothesizes that COL1A1 expression will correlate with ALP and DMP1 
expression with hydroxyproline for each subject. This study attempts to relate known 
biochemical markers of bone metabolism with known genetic markers to determine if a 





All tissue collection used for this study was from hip replacement operations that 
occurred between 2019 and 2020, before the COVID-19 hospital shutdown of elective 
surgeries. Before extraction, all patients' informed consent was gathered according to 
HIPAA guidelines (protocol BUSM IRB Number H-35199). The femoral head and neck 
samples were delivered to the lab within 30 minutes of the extraction. Patients with 
diseases affecting healthy bone, including sickle cell disease, rheumatoid arthritis, 
undergoing chemotherapy, or using bone metabolism modifying drugs such as those for 
osteoporosis, were excluded from the study. Participants included in this study 
represented various BMIs, ages, races, and sexes. See table 3 for participants’ 
demographic. 
Subject # Sex Age Side Race BMI (kg/m^2) 
227 F 47 R White 21.86 
230 F 53 R White 23.4 
233 M 70 R Black 27.08 
237 M 54 L White 31 
239 M 62 R Black 33.36 
240 M 36 R White 23.29 
245 F 59 R Black 31.26 
246 M 39 R Black 28.87 
247 M 47 L White 30.63 
248 M 56 L Black 33.09 
249 F 49 L Black 34.11 
250 M 73 L Black 27.82 
251 F 50 L White 21.16 
252 M 56 R Asian 32.01 
253 M 55 R White 29.13 
254 F 69 R White 25.11 
Table 3. Patient demographics. 
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The bone chips were placed on ice in the lab, then washed and isolated from other 
tissues manually on a 20 mm grid dish. Subsequently, they were bathed in a cold 1x 
phosphate-buffered solution frozen in liquid nitrogen and stored at -80 degrees Celsius 
until further processing. The reamings were weighed and washed with 100 mL of 
Dubeco's Phosphate Buffered Saline (D-PBS) and 10 mL 100x Antibiotic/Antimycotic 
solution. 
For the studies reported here cell cultures were prepared and biochemical assays 
carried out as per Margaret Dunlap (Demographic Variation in Bone-Marrow Derived 
Mesenchymal Stem Cell Analytes) Masters of Graduate Medical Sciences. Bone cells 
were isolated from the acetabular reamings and plated in DPBS, and maintained in an 
incubator at 37 degrees C, 5% CO2, >90% humidity. The cells were grown out in 
traditional media, and on the sixth day, an osteoinductive media made of 200 mL 
Osteogenic Differentiation Basal Medium, 50 mL 5X Supplement, 2.5 mL 200 mM L-
Glutamine, and 2.5 mL 100 X antibiotic-antimycotic was introduced.  After 27 days, the 
cell cultures were harvested except for one 6-well and one 24-well plate for each patient 
kept for assaying. The 6-well plate was used for other assays (3 wells) and RNA 
purification (3 wells). The 24-well plates were employed to assay ALP, total protein, total 
hydroxyproline, and total calcium. 
The study done by Ms. Dunlap measured the activity of ALP for each plate, 
including adding in each well 450 uL of ALP assay buffer (0.75 g of 0.1 M glycine per 
100 mL DI water and 9.5 mg 1mM MgCl2 per 100 mL DI water) and 50 uL ALP 
substrate (20 mg p-nitrophenol phosphate disodium salt in 1 mL DI water), on a plate and 
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incubated for 30 minutes at room temperature in a dark room. The prepared solution was 
distributed in a second plate with NaOH to neutralize the reaction, and the absorbance 
read at 410 nm. 
Assay analysis for hydroxyproline began after hydrolyzing 200 ul plated samples. 
The hydroxyproline assays were performed on a 96-well plate using a Sigma-Aldrich 
Hydroxyproline Assay kit. Using Stepwise dilutions of the standard solution created a 
standard curve. Each sample incubated with 100 uL of Chloramine T/Oxidation Buffer (6 
uL Chloramine T concentrate and 94 uL oxidation buffer) for 5 minutes and diluted with 
100 uL DMAB reagent (50 uL DMAB concentrate and 50 uL perchloric 
acid/isopropanol) was then added to each well and incubated at 60 degrees C for 90 
minutes. The absorbances for each sample read at 560 nm. 
DNA assays were run on each sample using 96- well microplates using Thermo 
Fisher Scientific PicoGreen dsDNA reagent kits and TE buffer (Tris and EDTA) to 
mitigate the effect of DNAses and a normalization factor of the ALP and hydroxyproline 
assays. Each plate's absorbance was read on a fluorescent plate reader at 
excitation/emission: 485/20 nm and 530/25 nm. 
Once Covid-19 protocols allowed laboratory projects to resume, RNA extraction 
was performed on the pre-existing cells saved from cell culture. The RNA of each sample 
was extracted using Qiazol Lysis Reagent and a Qiazol TissueLyser, followed by 
isopropanol. The extracted RNA was then put through a thermal cycler that induced 
reverse transcription. The complementary DNA (cDNA) resulting from this process was 
diluted either 1:25 or 1:5 with RNase-free water, was combined with universal PCR 
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Master Mix (from Applied Biosystems ®), and primer for the gene analysis (18S RNA, 
COL1A1, DMP1). Samples used for COL1A1 were diluted to 1:25, while samples for 
DMP1 were diluted 1:5 to try to detect the usually low gene expression of DMP1. RNase-
free water was used as a negative control. The qRT-PCR cycle ran on an Applied 
Biosystems 7300 Real-Time PCR System. The resulting data for COL1A1 and DMP1 to 
normalize to the constitutively expressed 18S RNA value was subtracted from the 
collected gene expression values to produce a DCt value. The lower the resulting DCt 
value, the higher the relative gene expression.  
The DNA assay was used to normalize the ALP and hydroxyproline assays for 
each sample. The Ct values for COL1A1 and DMP1 normalized against 18S RNA for 
each sample to find the average gene expression (DCt). A linear regression analysis 
completed to find any association between the biochemical assays and their associated 





 This research aimed to determine if an association could be made between the 
gene expression of osteoblasts in development stages and the compounds produced 
during associated steps in the bone formation process. An association investigated was 
between COL1A1 expression and ALP assayed in cell culture, and the DCt values 
derived from qRT-PCR results for COL1A1 are shown in Table 4. The COL1A1 DCt 
values were plotted against ALP assay values (normalized against DNA). Figure 5 
illustrates the resulting linear regression and R-square value for this regression.  
There was no statistically significant association between COL1A1 and ALP (R-
squared = 0.0125). 
 
Table 4. qRT-PCR results for COL1A1 DMP1 analysis. 
Patient # COL1A1 DCt DMP1 DCt  Patient # COL1A1 DCt DMP1 DCt 
227 13.4975 26.024 247 7.164 26.509 
230 10.3795 25.046 248 7.53 22.854 
233 12.5935 24.8 249 6.3035 26.583 
237 8.3125 21.634 250 8.7505 25.408 
239 5.4285 18.742 251 9.796 26.622 
240 16.6295 26.618 252 11.195 25.6135 
245 18.1995 26.578 253 5.446 26.405 




Figure 5. COL1A1 vs. ALP. 
 
 
DMP1 was plotted against hydroxyproline. In all but three patients, the RT-PCR 
machine assigned a Ct value of “Undetermined,” indicating that the gene expression was 
so low that the machine could not detect it. In these cases, a value of 40 (maximum value 
given by RT-PCR) was assigned. A DCt was calculated based on these assigned values, 
indicated in Table 4. Figure 6 shows the linear regression and R-squared value of the 
comparison between DMP1 expression and hydroxyproline.  














ALP vs. COL1A1 Expression
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There was no statistically significant association between these two values (R-
squared = 0.0129). Appendix 1 contains a more thorough breakdown of the ALP and 
hydroxyproline assay values.   
 
 





   





















Osteoporosis is a disease characterized by architectural fragility and impairment 
of BMD, which leads to an increased risk of fragility fractures in millions of people 
around the world. Certain fractures, such as at the hip or spine cause immobilization, and 
can lead to life-threatening complications, such as pneumonia or pulmonary embolism 
(Rachner). Currently, this disease is underreported, and many do not realize they have 
osteoporosis until their first fracture. The study of osteoporosis’s gene expression and 
pathophysiology are critical to the mitigation and prevention of this disease.  
This study focused on two aspects of bone formation: initiation and osteocyte 
formation. ALP was used as a proxy for bone formation. When osteoblasts are induced to 
begin forming bone, osteoblasts produce collagenous and non-collagenous proteins, such 
as ALP. Cultured cells were assayed for their ALP expression to indicate their metabolic 
state. Osteoblasts that expressed higher amounts of ALP were thought to be in a bone 
formation state. The expression of the COL1A1 gene was determined for each subject’s 
cell culture. COL1A1 is a gene that codes for type I collagen, a necessary component of 
bone formation. In this experiment, COL1A1 gene expression was compared to the 
amount of ALP present in the assay normalized against the amount of DNA present.  
The linear regression between COL1A1 and ALP showed no statistically 
significant association between these two values. There are a few possible explanations 
for this lack of association. The most pertinent is the ubiquity of type I collagen. While 
type I collagen is critical to the formation of bone, it is also a necessary product of most 
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connective tissues. The expression of COL1A1 may not be a satisfactory metric of 
osteoblast expression of bone growth. 
The other association studied in this paper was between the gene expression of 
DMP1 and hydroxyproline production in cell culture. Hydroxyproline is an amino acid 
critical to the production of collagen in the bone. After a bone breakdown, 
hydroxyproline is released and excreted and cannot be recycled. Hydroxyproline levels 
have been used as a metric of bone resorption and degradation in vivo by measuring the 
clearance in urine. Studies have linked hydroxyproline expression in osteoblast cell 
culture with bone breakdown and turnover. DMP1 gene expression occurs in the final 
stage of the bone formation cycle, transforming an osteoblast into an osteocyte.  
DMP1 gene expression was plotted against assayed hydroxyproline to determine 
if an association could be made between these late-stage bone formation indicators. The 
linear regression between DMP1 and hydroxyproline shows no statistically significant 
association. There are multiple potential causes of this result. The first is the mismatched 
association between the mineralization of bone indicated by DMP1 expression and the 
presence of hydroxyproline, which is present in osteoid more prevalently but diminishes 
as the matrix mineralizes during later stages of osteogenesis when osteocytes are more 
prevalent. 
 While these are both late-stage steps in the bone cycle, they are perhaps distinct 
enough that an association cannot be made between them. Additionally, the current 
testing metric for DMP1 proved to be somewhat faulty. The current qRT-PCR 
technology used to determine the expression is relatively sensitive; however, only 
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subjects 248, 250, and 252 in table 4 had measurable DMP1 expression. All other 
subjects either had no gene expression or gene expression past the measurable limit. An 
upper limit of 40 was assigned to all samples with an “undetermined” gene expression, 
which likely prevented detection of any actual association if present.  
Other feasible confounding factors could explain the lack of association between 
the test metrics. The first is the small sample size. Ultimately, the sample size of this 
experiment was 16 test subjects. Possibly a correlation could be made between COL1A1 
and ALP or between DMP1 and hydroxyproline with a larger sample size. Another factor 
was assuming the generalizability of osteoblast expression across population groups. In 
this experiment, regardless of age, race, sex, smoking status, or BMI, all subjects were 
treated the same. Additionally, considering one or more of these population conditions in 
the analysis could have resulted in an interaction.  
In terms of the experiment itself, modifications could be made to the experimental 
design to ensure proper RNA expression. The samples used in this RNA analysis were 
frozen from 2019 through early 2020 due to the COVID-19 shutdown. Ideally, the qRT-
PCR analysis done on RNA extracted from cells freshly removed from the culture may 









 Future experiments that include a higher number of test subjects could possibly 
provide a measured association between them. Additionally, the same data can be 
analyzed while controlling for race, age, sex, and BMI. The sample subjects used in this 
study all self-identified as White (non-Hispanic) or African American. Future studies 
should include Hispanic and Asian subjects to ensure the generalizability of the results 









Appendix 1: from Margaret Dunlap (Demographic Variation in Bone-Marrow Derived 
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